Protagenic Therapeutics, Inc. (OTCMKTS:PTIX) Files An 8-K Other Events
Item 8.01 Other Events.

Description

99.1

Press Release of Protagenic Therapeutics, Inc., dated September28, 2017.

Protagenic Therapeutics, Inc.new Exhibit
EX-99.1 2 ex_96060.htm EXHIBIT 99.1 ex_96060.htm Exhibit 99.1   Protagenic’s Neuropeptide Shows Strong Efficacy in Treating Depression and Anxiety of Established Rodent Models     ● First in class psychotropic agent   ● 50% reduction in anxiety related symptoms   ● Data generated by independent world-renowned laboratory   NEW YORK,…
To view the full exhibit click here

About Protagenic Therapeutics, Inc. (OTCMKTS:PTIX)

Protagenic Therapeutics, Inc., formerly Atrinsic, Inc., is a development-stage company. The Company is a biotechnology company that specializes in the discovery and development of therapeutics to treat central nervous system (CNS) disorders. The Company provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-base, brain active therapeutics. The Company has developed a portfolio of neuropeptides that are in various stages of development and preclinical evaluation for the treatment of various mood disorders. These neuropeptides are called PT00114, PT00121, PT00211, PT00311 and PT00411. As of September 30, 2016, the Company has not generated any revenue.